Researchers at the forefront of multiple sclerosis (MS) treatment have developed a groundbreaking experimental medication that has shown remarkable results in improving symptoms of the disease. The medication, known as CNM-Au8, contains gold nanocrystals and has the ability to cross the blood-brain barrier to enhance cellular energy and restore neurological function in MS patients.
A recent Phase 2 clinical trial presented at the American Academy of Neurology’s annual meeting involved 78 patients with relapsing MS. Two-thirds of the patients who were administered the gold liquid suspension reported significant physical and cognitive improvements compared to those who received a placebo. This promising development offers hope for MS patients who experience disease progression independent of relapse activity.
Moreover, the safety profile of CNM-Au8 was found to be excellent, with no significant adverse side effects reported by trial participants. This has paved the way for researchers to proceed to Phase 3 trials in order to further evaluate the medication’s effectiveness.
Patients who took part in the trial, such as Damian Kunko, have shared remarkable improvements in walking speed, balance, vision, cognitive function, and energy levels. Medical experts not involved in the medication’s development, including Dr. Marc Siegel and Dr. James Kuo, believe that the trial results demonstrate promise in modifying the disease and enhancing neurological health in MS patients.
Furthermore, researchers are exploring the potential for CNM-Au8 to address symptoms of other neurological disorders like ALS, Alzheimer’s, and Parkinson’s. The groundbreaking results of this medication offer a glimmer of hope for individuals battling these debilitating conditions. Stay tuned for more updates on this groundbreaking development in neurological health.
“Travel aficionado. Incurable bacon specialist. Tv evangelist. Wannabe internet enthusiast. Typical creator.”